Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis | ALNY Stock News
Harnessing Human Genetics to Power the Next Wave of RNAi Therapeutics | Alnylam® Newsroom
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults | Alnylam Pharmaceuticals, Inc.
Alnylam Receives Prestigious Massachusetts Economic Impact Award | Alnylam® Newsroom
Alnylam's expansion plan for Onpattro blocked by FDA | pharmaphorum
Building a Corporate Responsibility Program from the Ground Up: Key Learnings from Alnylam's Corporate Responsibility Journey | Alnylam® Newsroom
Alnylam® Pharmaceuticals
Alnylam Pharmaceuticals Inc. (@alnylampharma) • Photos et vidéos Instagram
Roche and Alnylam Strike $2.8 Billion RNAi Deal
Alnylam Named One of America's Most Responsible Companies by Newsweek for 2nd Year in a Row | Alnylam® Newsroom
Alnylam to face FDA Adcomm for Onpattro's ATTR-CM bid
Alnylam Named a Science Magazine Top Employer for 3rd Year in a Row | Alnylam® Newsroom
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels - PANTHERx Rare
Press Releases | Alnylam Pharmaceuticals, Inc.
Alnylam® Newsroom
Harnessing Human Genetics to Power the Next Wave of RNAi Therapeutics | Alnylam® Newsroom
Alnylam Pharmaceuticals Press Release | Feb 02, 2024
Alnylam announces positive results for Alzheimer's treatment
Articles about Alnylam Pharmaceuticals
FDA Denies Patisiran for Cardiomyopathy of ATTR Amyloidosis
Alnylam® Pharmaceuticals
FAP Candidate Vutrisiran May Have New Dosing Regimen, Alnylam Says
Alnylam Named One of Fast Company's Most Innovative Companies for 2023 | Alnylam® Newsroom
Alnylam Pharmaceuticals on X: "Today, we are delighted to announce that the European Commission (@EMA_news) approved our #RNAi therapeutic for the treatment of #hATTR #amyloidosis with stage 1 or 2 polyneuropathy, an
Alnylam® Newsroom
